Repare Therapeutics stock faces merger-driven reset

Published on 09/23/2026 at 03:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Repare Therapeutics stock is tied to a $2.1986 cash payment dated September 22, 2026. Shareholders also receive one RPTX share per former share.

RPTX, US76094Q1022, Illustration mit AI erstellt.

Repare Therapeutics Inc. (ISIN US76094Q1022) is undergoing a merger-related reset after a corporate-action notice dated September 22, 2026 specified a cash payment of USD 2.1986 and one RPTX share for each previously held share. The terms define the immediate reference point for Repare Therapeutics stock on September 23, 2026.

Merger terms set the reference value

According to Robinhood on September 22, 2026, the transaction provides USD 2.1986 in cash plus 1.0000 RPTX share for every former Repare Therapeutics share. That structure makes the cash component a concrete comparison point rather than a conventional earnings catalyst.

The numerical split matters because the consideration combines a fixed cash amount with equity exposure. The cash leg is USD 2.1986, while the share leg is exactly 1.0000 share, according to the same corporate-action notice.

Clinical value remains the key variable

Repare Therapeutics is a biotechnology issuer, so the value of the continuing equity component depends on the company assets and transaction structure rather than on a standard dividend or mature-company earnings multiple. The available corporate-action record identifies the merger consideration, but it does not provide a current revenue, earnings, cash-balance or clinical-readout figure for a fresh reporting period.

For investors assessing the September 23, 2026 setup, the clearest quantified checkpoint is therefore the merger consideration itself: USD 2.1986 in cash and 1.0000 RPTX share per former share. The two-part structure is materially different from a cash-only takeover because shareholders retain a precisely defined equity component.

Stock value follows transaction mechanics

Repare Therapeutics stock is best read through the announced corporate-action terms until a dated primary-exchange quotation and a new company report establish a different market reference. The transaction record supplies a concrete value comparison, but it does not by itself establish a Nasdaq closing price, daily percentage change, market capitalization or 52-week range for September 23, 2026.

The practical distinction is important: USD 2.1986 is the stated cash consideration, not a newly verified market quotation. The separate 1.0000-share component means the final economic value is linked to the value assigned to the RPTX equity issued or retained under the merger terms.